TrialAnnals of the rheumatic diseases2015

Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.

Jonas K Eriksson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.